濟民醫療(603222.SH):控股股東及一致行動人再次減持1.92%的股份
格隆匯9月17日丨濟民醫療(603222.SH)公佈,2021年9月15日,公司收到控股股東雙鴿集團有限公司(“雙鴿集團”)及一致行動人張雪琴通知,雙鴿集團及張雪琴分別通過上海證券交易所大宗交易方式減持公司股份330萬股(佔公司總股本的0.97%)、320萬股(佔公司總股本的0.94%)。自2021年5月13日至2021年9月15日,雙鴿集團及張雪琴通過大宗交易、集中競價交易方式減持公司股份,合計持股比例變動達到1.92%,距前次《控股股東及一致行動人減持股份進展暨減持超過 1%的提示性公吿》披露後減持比例已超過1%。
此次權益變動後(自公司首次公開發行股票至公吿日),雙鴿集團及其一致行動人合計持有公司股份數量為188,700,100股,佔公司總股本的55.38%,被動稀釋及主動減持合計持股比例減少8.43%(從63.81%減少至55.38%)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.